* Dynavax Technologies Corp DVAX.OQ reported quarterly
adjusted
earnings of 12 cents per share for the quarter ended September
30, higher than the same quarter last year, when the company
reported EPS of 10 cents. The mean expectation of five analysts
for the quarter was for earnings of 11 cents per share. Wall
Street expected results to range from 8 cents to 14 cents per
share.
* Revenue rose 16% to $80.63 million from a year ago;
analysts
expected $84.17 million.
* Dynavax Technologies Corp's reported EPS for the quarter
was 12
cents.
* The company reported quarterly net income of $17.59
million.
* Dynavax Technologies Corp shares had risen by 10.3% this
quarter and lost 12.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 3.4%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Dynavax
Technologies Corp is $27.00
This summary was machine generated from LSEG data November 8 at
05:06 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.11 0.12 Beat
Jun. 30 2024 0.06 0.08 Beat
Mar. 31 2024 -0.02 -0.07 Missed
Dec. 31 2023 -0.01 0.00 Beat